Core Insights - Biogen Inc. is recognized as one of the best-performing pharmaceutical stocks in 2025, with multiple rating updates from various financial institutions [1][2][3] Group 1: Rating Updates - Truist raised the price target for Biogen Inc. to $190 from $142 while maintaining a Hold rating, indicating that fundamental views remain unchanged for 2025 [1] - Goldman Sachs increased the price target to $225 from $197, keeping a Buy rating, and expects continued momentum in 2026 due to improving fundamentals and market dynamics [2] - Mizuho raised the price target to $207 from $177 and maintained an Outperformed rating, suggesting a more favorable outlook for 2026 [3] Group 2: Company Overview - Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for serious diseases, including multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, and amyotrophic lateral sclerosis [4] - The company's marketed product portfolio for multiple sclerosis includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, along with SPINRAZA for spinal muscular atrophy and SKYCLARYS for Friedreich's Ataxia [4]

In this article, we will look at the 10 Best Performing Pharma Stocks in 2025.On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook. He stated that M&A activity started off strong in the year, and that pharma stocks are set to take off in 2026.In addition to the big pharma companies, he believes that biotech, which had a really tough past 3-4 years, is ready to take of ...